Triferic Product & Market Opportunity - Triferic is the FIRST and ONLY FDA-approved therapy indicated to maintain hemoglobin levels in hemodialysis patients[5, 66] - Global Triferic market potential exceeds $1 billion[5, 10, 51, 52] - The U S market potential for Triferic is estimated at $400 million[47] - The company's base business generates over $60 million in revenue annually[5] Commercialization & Strategy - Dialysate Triferic U S commercial launch commenced in May 2019, establishing a foundation for I V Triferic[5, 14] - I V Triferic NDA was submitted in May 2019 with a PDUFA date of March 28, 2020[5, 14, 33] - The company is building a commercial and medical team of approximately 25 professionals to support Triferic adoption[41] Financial Performance - The company's sales were $63 4 million in FY 2018 and $57 3 million in FY 2017[56] - The operating loss was $32 4 million in FY 2018 and $25 9 million in FY 2017[57] - The company's cash and investments were $33 5 million[59]

Rockwell Medical, Inc. (NASDAQ:RMTI) Q2 2019 Results Conference Call August 8, 2019 4:30 PM ET Company Participants Ilanit Allen – Investor Relations Stuart Paul – President and Chief Executive Officer Angus Smith – Chief Financial Officer Conference Call Participants Nicole Gabreski – Piper Jaffray David Bouchey – IFS Securities Operator Good afternoon, ladies and gentlemen, and welcome to the Rockwell Medical 2019 Second Quarter Results Call. At this time all participants are in a listen-only mode. Later, ...

Rockwell Medical, Inc. Q1 2019 Earnings Call MAY 9, 2019 Forward Looking Language Certain statements in this presentation may constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "could," "plan," "potential," "predict," "forecast," "project," "plan", "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-lookin ...